Manulife to offer the Galleri cancer detection test

Manulife Canada announced it is the first insurance company in Canada to offer access to GRAIL’s Galleri multi-cancer early detection test, to eligible life insurance customers, through its Manulife Vitality program.

Manulife has partnered with Medcan , the official Canadian provider of GRAIL’s Galleri test. Through this collaboration, eligible Manulife customers will be able to access the test at Medcan’s Toronto and Oakville clinics with support from Medcan’s clinical team throughout the testing process – including pre-test counseling, results review, and next-step coordination.

The Galleri test will be offered at a reduced cost through the Manulife Vitality Plus program and is available to eligible members aged 50+. Through a single blood draw, the Galleri test can detect more than 50 types of cancer before symptoms appear.

Manulife’s collaboration with GRAIL began in 2022 through its U.S. unit, John Hancock, where the Galleri test is available to eligible life insurance customers and retirement plan participants.

“Manulife is proud to be at the forefront of innovation in Canadian insurance. By offering the Galleri test to eligible customers, we’re expanding access to cutting-edge health solutions that can potentially improve outcomes through early detection. Cancer has touched nearly every Canadian in some way. By offering this innovative screening tool, we’re giving Canadians a stronger start in the fight — one rooted in early detection and proactive care.” – Naveed Irshad, President and CEO, Manulife Canada.